Key result
Higher CTI linked to ~56% increased all-cause mortality risk per unit increase.
Why the study?
The combined prognostic value of metaflammation and vascular aging markers in cardiovascular-kidney-metabolic syndrome is unclear.
Do higher CTI and ePWV increase all-cause mortality in middle-aged and older adults?
Cohort (n=7,183)
Yes
Do higher CTI and ePWV increase all-cause mortality in middle-aged and older adults?
CTI and ePWV are accessible biomarkers that independently and jointly predict all-cause mortality, offering a practical tool for risk stratification in cardiovascular-kidney-metabolic syndrome.
Background and Aims The combined prognostic value of metaflammation and vascular aging markers in cardiovascular‐kidney‐metabolic (CKM) syndrome is unclear. This study aimed to assess the independent and joint associations of the C‐reactive protein‐triglyceride glucose index (CTI) and estimated pulse wave velocity (ePWV) with all‐cause mortality. Methods This prospective study included 7183 participants from the CHARLS 2011 survey (original cohort) and 9594 from 2015 (temporal sensitivity analysis cohort). Multivariable Cox models and restricted cubic splines were used. Joint effects were analyzed by median‐based groups, and mediation was tested using the KHB method. Results During follow‐up, 906 deaths occurred in the original cohort. Each 1‐unit increase in CTI was associated with a 56% higher mortality risk (HR = 1.56, 95% CI: 1.37–1.77), and each 1 m/s increase in ePWV with an 11% higher risk (HR = 1.11, 95% CI: 1.05–1.18). The high CTI/high ePWV group had the highest risk (HR = 1.73, 95% CI: 1.31–2.29). ePWV mediated 6.48% of the CTI‐mortality association, while CTI mediated 2.62% of the ePWV‐mortality association. These findings were confirmed in the temporal sensitivity analysis. Conclusion CTI and ePWV independently and jointly associate with increased all‐cause mortality. The observed bidirectional mediation suggests potentially interconnected pathways that warrant further investigation. Integrating these accessible biomarkers could improve risk stratification in CKM syndrome.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) conducted a cohort in Cardiovascular-kidney-metabolic (CKM) syndrome risk (n=7,183). C-reactive protein-triglyceride glucose index (CTI) and estimated pulse wave velocity (ePWV) vs. Lower levels of CTI and ePWV was evaluated on All-cause mortality (HR 1.56, 95% CI 1.37-1.77, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: